HCV Tappt Adherence Study

Hepatitis C Clinical Trial

Official title:

Effectiveness of a Novel Smart Tag Technology in a Pharmacy-Led Setting to Improve Adherence, Patient-Centered Care and Outcomes in HCV

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06263829
• Other study ID #: 2023-1580
• Status: Not yet recruiting
• Phase: N/A
• Start date: July 1, 2024
• Est. completion date: July 1, 2025

Study information

• Verified date: February 2024
• Source: University of Illinois at Chicago
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The goal of this non-inferiority clinical trial is to evaluate the efficacy of Tappt, a novel digital medication companion solution, among individuals with hepatitis C virus (HCV) who are starting a daily oral medication regimen following standard of care in a clinical pharmacy setting. - The primary aim is to assess the non-inferiority of Tappt with medication adherence, treatment completion, sustained virologic response (SVR) assessment, and SVR achievement rates. - The secondary aim is to assess the efficacy of Tappt at enabling pharmacists to personalize treatment and management decision based on participants' reported barriers to adherence, care, and SVR achievement. Participants will download and utilize the Tappt app to record adherence to oral medication. For the purposes of this study, adherence for participants in the intervention arm will be measured using a modified medication possession ratio (MPR) measure called medication tag scan ratio (MTSR). MTSR is defined as a percentage of the number of times participants scanned their passive tags versus the total of expected tag scans based on that participant's medication regimen and treatment period. Upon study completion, a retrospective matched control will be established for the intervention group. Historic data for the matched control's adherence, treatment completion, SVR assessment, and SVR rates will be compared to the intervention arm.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 30
• Est. completion date: July 1, 2025
• Est. primary completion date: January 1, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. 18 years of age or older

2. Hepatitis C virus (HCV) infection (denoted by positive HCV antibody and detectable HCV RNA)

3. Initiating oral HCV therapy with glecaprevir/pibrentasvir or sofosbuvir/velpatasvir

4. HCV treatment provided and managed by the clinical pharmacist at UI Health

5. Access to a mobile smartphone (iPhone 7 or later; Android release date 2012 or later) with reliable data and/or Wi-Fi access

6. Ability to verbalize understanding of the study protocol in English

7. Able and willing to provide informed consent in English

Exclusion Criteria:

1. Inability to speak and read English

2. Inability or unwillingness to adhere to the study protocol

3. Pregnant individuals

4. Decompensated cirrhosis (Child Turcotte Pugh Class B and C); hepatocellular carcinoma; prior liver or kidney transplant No patient will be excluded because of gender, race or ethnic origin.

The following populations will be excluded from the study:

• Adults 18 years of age and older who are unable or unwilling to consent
• Individuals less than 18 years old
• Pregnant individuals
• Prisoners

Related Conditions & MeSH terms

• Hepatitis C

Intervention

Other:
• Use of Tappt App
Use of Tappt, a novel digital medication companion solution

Locations

Country	Name	City	State
n/a

Sponsors (3)

Lead Sponsor	Collaborator
University of Illinois at Chicago	American Society of Health-System Pharmacists, Synchronyx

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Medication adherence	Modified medication possession ratio (MPR) measure called medication tag scan ratio (MTSR)	8-12 weeks